InvestorsHub Logo
Followers 0
Posts 1283
Boards Moderated 0
Alias Born 07/28/2019

Re: None

Monday, 06/01/2020 4:37:51 PM

Monday, June 01, 2020 4:37:51 PM

Post# of 18220
The company received the okay to proceed with phase 3 trail “Cytocom intends to immediately move forward with its IND 067442 submission for the Phase 3 pivotal clinical program for moderate to severe Crohn’s disease in patients 12 and over.”